Advances in Bacterial Vaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 225
Special Issue Editors
Interests: vaccines; mucosal delivery; preclinical development
Special Issue Information
Dear Colleagues,
Despite the long history of bacterial vaccines development, there is still an urgent need for new and improved vaccines and the field is constantly developing and improving. The increase in antimicrobial resistance ensures the continued use of vaccines is still the best way to control infection by inducing protective immunity against all the strains, including those that are antibiotic resistant. However, there is increasing evidence that bacterial pathogens are evolving to evade current vaccines as in the case of pertussis. Some vaccines induce short term protection requiring the administration of multiple doses. There are also large number of bacterial diseases for which there are no licensed vaccines such as Group A and Group B Streptococcus, Clostridium difficile and many other bacterial pathogens.
Traditionally bacterial vaccines have been composed of toxoids, killed or live attenuated whole cells, purified subunits, polysaccharides or conjugates. However, advances in new technologies and methods such as recombinant protein technology, viral vector and mRNA have been successfully used in bacterial vaccines development.
Adjuvants are used to improve the efficacy of vaccines and the most widely used being alum salts which tend to induce a more humoral response when a cellular response is required for more efficient control of infection. Some other adjuvants such as MF59, ASO1, 3 and 4 and CPG have been recently used in some vaccines, but we still don’t fully understand their molecular mechanisms of function and reactogenicity. Development of new potent and safe adjuvants is also a field for constant development.
Moreover, development of successful vaccines requires the use of appropriate animal models, development of correlates of protection and standardized assays to evaluate their safety and potency and support their licensing.
To achieve a more extensive understanding of recent scientific knowledge and trends in bacterial vaccine development, this Special issue is focused on the recent scientific and technical progresses made in this field. Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation or review, to highlight (i) improvements of traditional vaccines (ii) development of vaccines against diseases which currently have no licensed vaccines (iii) the use of new technologies for bacterial vaccines (iv) improved adjuvants (v) correlates of protection.
Dr. Fatme Mawas
Dr. Kevin Markey
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bacterial vaccines
- preclinical
- potency
- safety
- adjuvant
- delivery
- correlate of protection
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
